Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.68 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.65 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | TYMS | P04818 | 3/20 | 0.52 |
| ▸ | AHR | P35869 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9571719 | 0.88 | HSPA1A (0.69) | ADORA2AHSPA1APABPC1DPP4TYMS | |
| SCHEMBL13479534 | 0.85 | ADORA2A (0.63) | ADORA2AHSPA1APABPC1DPP4TYMS | |
| SCHEMBL18132358 | 0.82 | CA9 (0.71) | CA9CA12SCN2ACA1CA2 | |
| SCHEMBL31061260 | 0.81 | ADORA2A (1.00) | ADORA2AHSPA1APABPC1DPP4AHR | |
| SCHEMBL9566604 | 0.81 | HSPA1A (0.77) | ADORA2AHSPA1APABPC1DPP4AHR | |
| SCHEMBL14881886 | 0.80 | KDM4E (0.57) | TYMSAHRCA9CA12SCN2A | |
| SCHEMBL11513204 | 0.79 | HSPA1A (1.00) | ADORA2AHSPA1APABPC1DPP4TYMS | |
| SCHEMBL31259838 | 0.79 | HSPA1A (1.00) | ADORA2AHSPA1APABPC1DPP4TYMS | |
| SCHEMBL16589414 | 0.79 | CA9 (0.75) | CA9CA12SCN2ACA1CA2 | |
| SCHEMBL9566623 | 0.78 | HSPA1A (0.73) | ADORA2AHSPA1APABPC1DPP4TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3087069-B1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | NORGINE BV (NL) | 2019-01-30 | — | — | EP | disclosed |
| US-9969687-B2 | Compounds useful as CCR9 modulators | NORGINE B.V. (NL) | 2018-05-15 | — | — | US | disclosed |
| US-20170001959-A1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | NORGINE B.V. (NL) | 2017-01-05 | — | — | US | disclosed |
| US-20170001959-A1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | NORGINE B.V. (NL) | 2017-01-05 | — | — | US | disclosed |
| EP-3087069-A1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | Norgine BV (NL) | 2016-11-02 | — | — | EP | disclosed |
| WO-2015097121-A9 | COMPOUNDS USEFUL AS CCR9 MODULATORS | NORGINE B.V. (NL) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015097121-A9 | COMPOUNDS USEFUL AS CCR9 MODULATORS | NORGINE B.V. (NL) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015097121-A1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | NORGINE B.V. (NL) | 2015-07-02 | — | — | WO | disclosed |
| WO-2015097121-A1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | NORGINE B.V. (NL) | 2015-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001959-A1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | CCR9, CCR1, CCR10 | ADORA2A 349/4885HSPA1A 2702/4885PABPC1 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.